Findings Highlighted In Oral and Poster Presentations at 2013
The study results were featured in an oral presentation delivered by
Additional program results were featured in a poster presentation, Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients (Abstract 2288).
To generate these results, the researchers applied Nodality’s proprietary technology-benefits.html&esheet=50737683&newsitemid=20131028005529&lan=en-US&anchor=SCNP+technology&index=3&md5=16ba9b0d3a825cebd77151240fa8a588" rel="nofollow">SCNP technology, a multiparametric flow cytometry-based assay that reveals functional biology by measuring the activity of protein pathway signaling at the single cell level.
About Single Cell Network Profiling
Single Cell Network Profiling (SCNP) is a proprietary technology licensed from
Nodality is a next-generation life sciences company that is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to reveal biology, define disease, and improve health. Nodality's unique, innovative, and proprietary platform, Single Cell Network Profiling or SCNP, enables the promise of precision medicine by unlocking the potential of therapeutics and by matching therapies with the right patients. SCNP enables functional characterization of disease-associated signaling at the individual patient level, enabling optimization of treatment tailored to target the biology driving the disease. Nodality is applying SCNP to develop molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the lead products targeting treatment management in hematological malignancies. Nodality is also collaborating with Pharma partners on patient stratification & companion diagnostics development, drug & disease profiling, determination of mechanism of action, mechanism-based competitive differentiation, whole blood PD assays, and biomarker discovery & development. These applications can result in increased probability of success, reduced timeline for clinical development, and differentiation from competitors in the marketplace. Nodality established multi-year pharma strategic collaborations with